Обзорная статья

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Hartmut DöhnerDepartment of Internal Medicine III, University of Ulm, Ulm, Germany;Elihu H. EsteySeattle Cancer Center Alliance, WA;Sergio AmadoriDepartment of Hematology, Tor Vergata University Hospital, Rome, Italy;Frederick R. AppelbaumClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;Thomas BüchnerDepartment of Hematology/Oncology, University of Münster, Münster, Germany;Alan K. BurnettDepartment of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom;Hervé DombretInstitut Universitaire d‘Hématologie Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris, Paris, France;Pierre FenauxService d'Hématologie Clinique, Hôpital Avicenne, Bobigny, France;David GrimwadeDepartment of Medical and Molecular Genetics, Guy's King's and St. Thomas' School of Medicine, London, United Kingdom;Richard A. LarsonDepartment of Medicine and Cancer Research Center, University of Chicago, IL;Francesco Lo‐CocoDepartment of Biopathology, University Tor Vergata and Santa Lucia Foundation at Centro Europeo per la Ricerca sul Cervello, Rome, Italy;Tomoki NaoeDepartment of Hematology, Nagoya University Hospital, Showa-ku, Japan;Dietger NiederwieserDepartment of Hematology, Oncology and Hemostasis, University of Leipzig, Leipzig, Germany;Gert J. OssenkoppeleDepartment of Haematology, VU University Medical Center, Amsterdam, The Netherlands;Miguel Á. SanzHematology and Bone Marrow Transplant Unit, University Hospital La Fe, Valencia, Spain;Jorge SierraClinical Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;Martin S. TallmanDivision of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL;Bob LöwenbergDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; andClara D. BloomfieldThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus

2009en

ABI

Аннотация

In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.

Перевод пока недоступен

Идентификаторы

DOI: 10.1182/blood-2009-07-235358

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar